Guest guest Posted October 22, 2006 Report Share Posted October 22, 2006 Quite a few links on that on my webpage from articles written and posted in the last few years - Yazbak, Tenpenny and others exposed that http://www.nccn.net/~wwithin/flu.htm Sheri At 06:13 PM 10/21/2006 -0700, you wrote: >So where do they come up with these inflated numbers like 30,000 or so people dying from the flu? > Sheri B. > >Donna <donna.arnold@...> wrote: > In 2001, just 257 people died from the flu. > > -------------------------------------------------------- Sheri Nakken, R.N., MA, Hahnemannian Homeopath Vaccination Information & Choice Network, Nevada City CA & Wales UK $$ Donations to help in the work - accepted by Paypal account earthmysteriestours@... voicemail US 530-740-0561 (go to http://www.paypal.com) or by mail Vaccines - http://www.nccn.net/~wwithin/vaccine.htm Vaccine Dangers On-Line course - http://www.nccn.net/~wwithin/vaccineclass.htm Reality of the Diseases & Treatment - http://www.nccn.net/~wwithin/vaccineclass.htm Homeopathy On-Line course - http://www.nccn.net/~wwithin/homeo.htm Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 17, 2006 Report Share Posted November 17, 2006 Some interesting links to info about the flu vaccine - http://www.nccn.net/~wwithin/flu.htm http://www.whale.to/vaccines/flu.html - this one has package inserts on it. http://www.planetc1.com/cgi-bin/n/v.cgi?c=1 & id=1163608370 Flu Vaccine increases risk for neurological disorderplanetc1.com-news@5:32 am PST by Dorausch, DCplanetc1.com news staff It is important to be aware of the risks involved when considering taking any drug or vaccine or putting a drug or vaccine into a young ones body. A new study has revealed that the flu vaccine is associated with an increased risk of developing a debilitating neurological disorder known as Guillain-Barré syndrome. The debilitating nerve destroying syndrome affects about one in 100,000 people each year. It results from the body's immune system attacking parts of the nervous system, causing weakness or tingling that can eventually lead to paralysis. Previous research had linked Guillain-Barré syndrome to the flu vaccine, but researchers continue to look for more connections between debilitating conditions and flu vaccines. According to the National Institute of Neurological Disorders and Stroke, Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the patient is almost totally paralyzed. The research comes from the University of Toronto. Researchers studied residents in Ontario, where a flu vaccine immunization program was started in 2000. All Ontario residents 6 months or older received a FREE flu vaccine. Researchers looked into cases of hospitalization for Guillain-Barré syndrome from 1993 to 2004. They then researched who had received a flu vaccine and compared the individuals risk for the syndrome within two to seven weeks after vaccination up to twenty to forty-three weeks later. Researchers also compared the number of Guillain-Barré cases before and after the immunization program began in 2000. Researchers discovered that Ontario residents were more likely to be hospitalized for Guillain-Barré syndrome in the two to seven weeks after being vaccinated than at forty-three weeks. It showed a small but increased risk for the disease after vaccination. There has been a lot of discussion whether the flu vaccine is even effective in preventing the flu. Add to that, the risk of developing disabling nerve disorders, mercury toxicity (from shots containing thimerosal), as well as other side effects, and you may wonder we one would even subject themselves to the shot. One thing is for sure, the more people that get the flu shot, the more data researchers will have to determine what disorders and conditions are caused by the shot. -- Doing a pubmed search for "Guillain-Barré syndrome flu vaccine" yielded these results: A case of influenza vaccination induced Guillain Barre syndrome with normal cerebrospinal fluid protein and improvement on treatment with corticosteroids. Eckert T, Bartels C, Mawrin C, Feistner H, Welte T. Department of Pneumology, Medical School of Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. We report a case of a 62-y-old male developing an influenza vaccination induced Guillain Barre syndrome (GBS) showing all clinical and neuropathological symptoms of GBS except the characteristic elevation of protein levels in the cerebrospinal fluid. The patient improved under treatment with 100 mg prednisolone. In these cases the administration of corticosteroids might be considered as a treatment option as they might represent a subgroup of GBS with a different immunological response pattern. PMID: 16138440 [PubMed - indexed for MEDLINE] ----- Guillain-Barre syndrome following influenza vaccination. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Ga 30333, USA. PHaber@... CONTEXT: An unexplained increase in the risk of Guillain-Barre syndrome (GBS) occurred among recipients of the swine influenza vaccine in 1976-1977. Guillain-Barre syndrome remains the most frequent neurological condition reported after influenza vaccination to the Vaccine Adverse Events Reporting System (VAERS) since its inception in 1990. OBJECTIVE: To evaluate trends of reports to VAERS of GBS following influenza vaccination in adults. DESIGN, SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous reporting system for adverse events following vaccination. Reports of GBS in persons 18 years or older following influenza vaccination were evaluated for each influenza season from July 1, 1990, through June 30, 2003. The number of people vaccinated was estimated from the National Health Interview Survey and US census data. Beginning in 1994, active follow-up was conducted to verify GBS diagnosis and obtain other clinical details. MAIN OUTCOME MEASURE: Reporting rates of GBS following influenza vaccination over time. RESULTS: From July 1990 through June 2003, VAERS received 501 reports of GBS following influenza vaccination in adults. The median onset interval (13 days) was longer than that of non-GBS reports of adverse events after influenza vaccine (1 day) (P<.001). The annual reporting rate decreased 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to 0.04 in 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of reports. Preceding illness within 4 weeks of vaccination was identified in 24% of reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting rates of GBS after influenza vaccination decreased. The long onset interval and low prevalence of other preexisting illnesses are consistent with a possible causal association between GBS and influenza vaccine. These findings require additional research, which can lead to a fuller understanding of the causes of GBS and its possible relationship with influenza vaccine. PMID: 15562126 [PubMed - indexed for MEDLINE] --- Influenza vaccination and Guillain Barre syndrome small star, filled. Geier MR, Geier DA, Zahalsky AC. The Genetic Centers of America, 14 Redgate Court, Silver Spring, MD 20905, USA. mgeier@... <mgeier@...> Acute and severe Guillain Barre Syndrome (GBS) cases reported following influenza vaccine to the Vaccine Adverse Events Reporting System (VAERS) database from 1991 through 1999 were examined. Endotoxin concentrations were measured using the Limulus amebocyte lysate assay in influenza vaccines. There were a total of 382 cases of GBS reported to the VAERS database following influenza vaccination (male/female ratio, 1.2). The median onset of GBS following influenza vaccine was 12 days (interquartile range, 7 days to 21 days). There was an increased risk of acute GBS (relative risk, 4.3; 95% confidence interval, 3.0 to 6.4) and severe GBS (relative risk, 8.5; 95% confidence interval, 3.7 to 18.9) in comparison to an adult tetanus-diphtheria (Td) vaccine control group. There were maximums in the incidence of GBS following influenza vaccine that occurred approximately every third year (1993, 1996, and 1998) and statistically significant variation in the incidence of GBS among different influenza manufacturers. Influenza vaccines contained from a 125- to a 1250-fold increase in endotoxin concentrations in comparison to an adult Td vaccine control and endotoxin concentrations varied up to 10-fold among different lots and manufacturers of influenza vaccine. The biologic mechanism for GBS following influenza vaccine may involve the synergistic effects of endotoxin and vaccine-induced autoimmunity. There were minimal potential reporting biases in the data reported to the VAERS database in this study. Patients should make an informed consent decision on whether to take this optional vaccine based upon its safety and efficacy and physicians should vigilantly report GBS following influenza vaccination to the VAERS in the United States so that continued evaluation of the safety of influenza vaccine may be undertaken. PMID: 12763480 [PubMed - indexed for MEDLINE] Qadoshyah Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 17, 2006 Report Share Posted November 17, 2006 Dear Qadoshyah, Thank you for this info. I have been struggling with this as Jack is scheduled for heart surgery very soon and I have not gotten the shot yet. (Or shots I should say.) All of his drs. recommend it. It is scary but, the package info. actually says in the contra- indications portion that it should not be administered to anyone with thimerosol sensitivity--I thought Fluzone was thimerosol free! Is it possible that the vaccine has been altered since the package insert was printed or that they change this each year? It also says not to administer to anyone under 6mos. of age. or who has a fever or any sign of illness. Aren't our heart babies chronically ill? This is supposed to be a dead vaccine--what is in there to cause these problems? You don't have to answer these ?? they are just my feeble brain ramblings!! Thankfully, God is still on His throne! Z. > > Some interesting links to info about the flu vaccine - > > http://www.nccn.net/~wwithin/flu.htm > > http://www.whale.to/vaccines/flu.html - this one has package inserts on it. > > > http://www.planetc1.com/cgi-bin/n/v.cgi?c=1 > <http://www.planetc1.com/cgi-bin/n/v.cgi?c=1 & id=1163608370> & id=1163608370 > Flu Vaccine increases risk for neurological disorder > planetc1.com-news@5:32 am PST <mailto:mail@...> email to the > editor > by Dorausch, DC > planetc1.com news staff > > It is important to be aware of the risks involved when considering taking > any drug or vaccine or putting a drug or vaccine into a young ones body. A > new study has revealed that the flu vaccine is associated with an increased > risk of developing a debilitating neurological disorder known as > Guillain-Barré syndrome. > > > The debilitating nerve destroying syndrome affects about one in 100,000 > people each year. It results from the body's immune system attacking parts > of the nervous system, causing weakness or tingling that can eventually lead > to paralysis. Previous research had linked Guillain-Barré syndrome to the > flu vaccine, but researchers continue to look for more connections between > debilitating conditions and flu vaccines. > > > According to the National Institute of Neurological Disorders and Stroke, > Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in which the body's > immune system attacks part of the peripheral nervous system. The first > symptoms of this disorder include varying degrees of weakness or tingling > sensations in the legs. In many instances the weakness and abnormal > sensations spread to the arms and upper body. These symptoms can increase in > intensity until certain muscles cannot be used at all and, when severe, the > patient is almost totally paralyzed. > > > The research comes from the University of Toronto. Researchers studied > residents in Ontario, where a flu vaccine immunization program was started > in 2000. All Ontario residents 6 months or older received a FREE flu > vaccine. Researchers looked into cases of hospitalization for Guillain-Barré > syndrome from 1993 to 2004. They then researched who had received a flu > vaccine and compared the individuals risk for the syndrome within two to > seven weeks after vaccination up to twenty to forty-three weeks later. > Researchers also compared the number of Guillain-Barré cases before and > after the immunization program began in 2000. > > > Researchers discovered that Ontario residents were more likely to be > hospitalized for Guillain-Barré syndrome in the two to seven weeks after > being vaccinated than at forty-three weeks. It showed a small but increased > risk for the disease after vaccination. > > > There has been a lot of discussion whether the flu vaccine is even effective > in preventing the flu. Add to that, the risk of developing disabling nerve > disorders, mercury toxicity (from shots containing thimerosal), as well as > other side effects, and you may wonder we one would even subject themselves > to the shot. One thing is for sure, the more people that get the flu shot, > the more data researchers will have to determine what disorders and > conditions are caused by the shot. > > -- Doing a pubmed search for " Guillain-Barré syndrome flu > vaccine " yielded these results: > > > A case of influenza vaccination induced Guillain Barre syndrome with normal > cerebrospinal fluid protein and improvement on treatment with > corticosteroids. > > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Eckert+T%22%5BAuthor%5D> Eckert T, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Bartels+C%22%5BAuthor%5D> Bartels C, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Mawrin+C%22%5BAuthor%5D> Mawrin C, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Feistner+H%22%5BAuthor%5D> Feistner H, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Welte+T%22%5BAuthor%5D> Welte T. > > Department of Pneumology, Medical School of Hannover, Carl-Neuberg- Str. 1, > 30625 Hannover, Germany. > > We report a case of a 62-y-old male developing an influenza vaccination > induced Guillain Barre syndrome (GBS) showing all clinical and > neuropathological symptoms of GBS except the characteristic elevation of > protein levels in the cerebrospinal fluid. The patient improved under > treatment with 100 mg prednisolone. In these cases the administration of > corticosteroids might be considered as a treatment option as they might > represent a subgroup of GBS with a different immunological response pattern. > > PMID: 16138440 [PubMed - indexed for MEDLINE] > > > > ----- > > > > > Guillain-Barre syndrome following influenza vaccination. > > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Haber+P%22%5BAuthor%5D> Haber P, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22DeStefano+F%22%5BAuthor%5D> DeStefano F, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Angulo+FJ%22%5BAuthor%5D> Angulo FJ, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Iskander+J%22%5BAuthor%5D> Iskander J, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Shadomy+SV%22%5BAuthor%5D> Shadomy SV, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Weintraub+E%22%5BAuthor%5D> Weintraub E, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Chen+RT%22%5BAuthor%5D> Chen RT. > > Immunization Safety Branch, Epidemiology and Surveillance Division, National > Immunization Program, Centers for Disease Control and Prevention, Atlanta, > Ga 30333, USA. PHaber@... > > CONTEXT: An unexplained increase in the risk of Guillain-Barre syndrome > (GBS) occurred among recipients of the swine influenza vaccine in 1976-1977. > Guillain-Barre syndrome remains the most frequent neurological condition > reported after influenza vaccination to the Vaccine Adverse Events Reporting > System (VAERS) since its inception in 1990. OBJECTIVE: To evaluate trends of > reports to VAERS of GBS following influenza vaccination in adults. DESIGN, > SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous reporting > system for adverse events following vaccination. Reports of GBS in persons > 18 years or older following influenza vaccination were evaluated for each > influenza season from July 1, 1990, through June 30, 2003. The number of > people vaccinated was estimated from the National Health Interview Survey > and US census data. Beginning in 1994, active follow-up was conducted to > verify GBS diagnosis and obtain other clinical details. MAIN OUTCOME > MEASURE: Reporting rates of GBS following influenza vaccination over time. > RESULTS: From July 1990 through June 2003, VAERS received 501 reports of GBS > following influenza vaccination in adults. The median onset interval (13 > days) was longer than that of non-GBS reports of adverse events after > influenza vaccine (1 day) (P<.001). The annual reporting rate decreased > 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to 0.04 in > 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of reports. > Preceding illness within 4 weeks of vaccination was identified in 24% of > reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting rates of GBS > after influenza vaccination decreased. The long onset interval and low > prevalence of other preexisting illnesses are consistent with a possible > causal association between GBS and influenza vaccine. These findings require > additional research, which can lead to a fuller understanding of the causes > of GBS and its possible relationship with influenza vaccine. > > PMID: 15562126 [PubMed - indexed for MEDLINE] > > > > --- > > > > > Influenza vaccination and Guillain Barre syndrome small star, filled. > > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Geier+MR%22%5BAuthor%5D> Geier MR, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Geier+DA%22%5BAuthor%5D> Geier DA, > > * > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=pubmed & cmd=Search & itool=pu > bmed_AbstractPlus & term=%22Zahalsky+AC%22%5BAuthor%5D> Zahalsky AC. > > The Genetic Centers of America, 14 Redgate Court, Silver Spring, MD 20905, > USA. mgeier@... <mgeier@...> > > Acute and severe Guillain Barre Syndrome (GBS) cases reported following > influenza vaccine to the Vaccine Adverse Events Reporting System (VAERS) > database from 1991 through 1999 were examined. Endotoxin concentrations were > measured using the Limulus amebocyte lysate assay in influenza vaccines. > There were a total of 382 cases of GBS reported to the VAERS database > following influenza vaccination (male/female ratio, 1.2). The median onset > of GBS following influenza vaccine was 12 days (interquartile range, 7 days > to 21 days). There was an increased risk of acute GBS (relative risk, 4.3; > 95% confidence interval, 3.0 to 6.4) and severe GBS (relative risk, 8.5; 95% > confidence interval, 3.7 to 18.9) in comparison to an adult > tetanus-diphtheria (Td) vaccine control group. There were maximums in the > incidence of GBS following influenza vaccine that occurred approximately > every third year (1993, 1996, and 1998) and statistically significant > variation in the incidence of GBS among different influenza manufacturers. > Influenza vaccines contained from a 125- to a 1250-fold increase in > endotoxin concentrations in comparison to an adult Td vaccine control and > endotoxin concentrations varied up to 10-fold among different lots and > manufacturers of influenza vaccine. The biologic mechanism for GBS following > influenza vaccine may involve the synergistic effects of endotoxin and > vaccine-induced autoimmunity. There were minimal potential reporting biases > in the data reported to the VAERS database in this study. Patients should > make an informed consent decision on whether to take this optional vaccine > based upon its safety and efficacy and physicians should vigilantly report > GBS following influenza vaccination to the VAERS in the United States so > that continued evaluation of the safety of influenza vaccine may be > undertaken. > > PMID: 12763480 [PubMed - indexed for MEDLINE] > > > > Qadoshyah > <http://www.geocities.com/dsinfo05/home.html> > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 17, 2006 Report Share Posted November 17, 2006 http://www.fluvaccine.net/web_files/2005-06_package_insert.pdf The thimerosal issue is not mentioned in the 2005-06 insert. I read that it was being manufactured on the same lines where thimerosol was used, hence the contradictions. Just like people with peanut allergies can't consume foods that don't contain peanuts, but were manufactured in a plant where peanuts share the same space or conveyor belt at times. And no.. a heart defect is not the same as having an active infection. You shouldn't vaccinate with anything if your child is fighting a viral or bacterial infection! That is what they are saying. Go on to read who they recomends getting the shot... lots of chronic illness there. Even people with AIDS are high on the list of people they want to get it. I don't know about the age issue. How old is Jack? ( nice name!! I have a Jack too.. he is 21 ) That would be something you would need to ask the Dr about, or call the company that makes the flu shot. I called the people who make the synegisis shot and had a nice long conversation with them way back when..... answered all my questions. Do what ever you need to do to feel confident in your decision, no matter which way you choose. The reason they want heart kids to get vaccinated is if they get a nasty viral or bacterial infection in the lungs before or right after the repair, they have a very hard time fighting it off due to low O2 levels and lack of strength. After the repair, immunity takes a big dip due to all the blood products they recieve so anything that give them a leg up is welcome. You are also going to be in the hospital during the viral season, so that puts him at a higher risk of catching these things since lots of sick people will be there with him. Many heart repairs are scheduled in summer in an effort to reduce that risk, but sometimes the kids just can't wait. You have to delay vaccinations before and after surgery. That information is posted on the CDC's site.. I can't remember the time frame anymore, sorry. It was 4 -8 weeks, I think!! btw- are you donating your own blood for his repair? The reason I ask, is there is a bit work involved in that and you should start asking questions now if that was your plan. Carol in IL Mom to seven including , 6 with TOF, AVcanal, GERD, LS, Asthma, subglottal stenosis, chronic constipation ( cured now ) and DS. My problem is not how I look. It's how you see me. Re: The Flu Vaccine Dear Qadoshyah,Thank you for this info. I have been struggling with this as Jack is scheduled for heart surgery very soon and I have not gotten the shot yet. (Or shots I should say.) All of his drs. recommend it. It is scary but, the package info. actually says in the contra-indications portion that it should not be administered to anyone with thimerosol sensitivity- -I thought Fluzone was thimerosol free! Is it possible that the vaccine has been altered since the package insert was printed or that they change this each year? It also says not to administer to anyone under 6mos. of age. or who has a fever or any sign of illness. Aren't our heart babies chronically ill? This is supposed to be a dead vaccine--what is in there to cause these problems? You don't have to answer these ?? they are just my feeble brain ramblings!! Thankfully, God is still on His throne! Z.>> Some interesting links to info about the flu vaccine - > > http://www.nccn. net/~wwithin/ flu.htm> > http://www.whale. to/vaccines/ flu.html - this one has package inserts on it.> > > http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1> <http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1 & id=116360837 0> & id=1163608370> Flu Vaccine increases risk for neurological disorder> planetc1.com- news@5:32 am PST <mailto:mail@ ...> email to the> editor> by Dorausch, DC> planetc1.com news staff > > It is important to be aware of the risks involved when considering taking> any drug or vaccine or putting a drug or vaccine into a young ones body. A> new study has revealed that the flu vaccine is associated with an increased> risk of developing a debilitating neurological disorder known as> Guillain-Barré syndrome. > > > The debilitating nerve destroying syndrome affects about one in 100,000> people each year. It results from the body's immune system attacking parts> of the nervous system, causing weakness or tingling that can eventually lead> to paralysis. Previous research had linked Guillain-Barré syndrome to the> flu vaccine, but researchers continue to look for more connections between> debilitating conditions and flu vaccines. > > > According to the National Institute of Neurological Disorders and Stroke,> Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in which the body's> immune system attacks part of the peripheral nervous system. The first> symptoms of this disorder include varying degrees of weakness or tingling> sensations in the legs. In many instances the weakness and abnormal> sensations spread to the arms and upper body. These symptoms can increase in> intensity until certain muscles cannot be used at all and, when severe, the> patient is almost totally paralyzed. > > > The research comes from the University of Toronto. Researchers studied> residents in Ontario, where a flu vaccine immunization program was started> in 2000. All Ontario residents 6 months or older received a FREE flu> vaccine. Researchers looked into cases of hospitalization for Guillain-Barré> syndrome from 1993 to 2004. They then researched who had received a flu> vaccine and compared the individuals risk for the syndrome within two to> seven weeks after vaccination up to twenty to forty-three weeks later.> Researchers also compared the number of Guillain-Barré cases before and> after the immunization program began in 2000. > > > Researchers discovered that Ontario residents were more likely to be> hospitalized for Guillain-Barré syndrome in the two to seven weeks after> being vaccinated than at forty-three weeks. It showed a small but increased> risk for the disease after vaccination. > > > There has been a lot of discussion whether the flu vaccine is even effective> in preventing the flu. Add to that, the risk of developing disabling nerve> disorders, mercury toxicity (from shots containing thimerosal), as well as> other side effects, and you may wonder we one would even subject themselves> to the shot. One thing is for sure, the more people that get the flu shot,> the more data researchers will have to determine what disorders and> conditions are caused by the shot.> > -- Doing a pubmed search for "Guillain-Barré syndrome flu> vaccine" yielded these results:> > > A case of influenza vaccination induced Guillain Barre syndrome with normal> cerebrospinal fluid protein and improvement on treatment with> corticosteroids.> > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Eckert+ T%22%5BAuthor% 5D> Eckert T, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Bartels+ C%22%5BAuthor% 5D> Bartels C, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Mawrin+ C%22%5BAuthor% 5D> Mawrin C, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Feistner +H%22%5BAuthor% 5D> Feistner H, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Welte+ T%22%5BAuthor% 5D> Welte T. > > Department of Pneumology, Medical School of Hannover, Carl-Neuberg-Str. 1,> 30625 Hannover, Germany.> > We report a case of a 62-y-old male developing an influenza vaccination> induced Guillain Barre syndrome (GBS) showing all clinical and> neuropathological symptoms of GBS except the characteristic elevation of> protein levels in the cerebrospinal fluid. The patient improved under> treatment with 100 mg prednisolone. In these cases the administration of> corticosteroids might be considered as a treatment option as they might> represent a subgroup of GBS with a different immunological response pattern.> > PMID: 16138440 [PubMed - indexed for MEDLINE]> > > > -----> > > > > Guillain-Barre syndrome following influenza vaccination.> > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Haber+ P%22%5BAuthor% 5D> Haber P, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22DeStefan o+F%22%5BAuthor% 5D> DeStefano F, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Angulo+ FJ%22%5BAuthor% 5D> Angulo FJ, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Iskander +J%22%5BAuthor% 5D> Iskander J, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Shadomy+ SV%22%5BAuthor% 5D> Shadomy SV, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Weintrau b+E%22%5BAuthor% 5D> Weintraub E, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Chen+ RT%22%5BAuthor% 5D> Chen RT. > > Immunization Safety Branch, Epidemiology and Surveillance Division, National> Immunization Program, Centers for Disease Control and Prevention, Atlanta,> Ga 30333, USA. PHaber@...> > CONTEXT: An unexplained increase in the risk of Guillain-Barre syndrome> (GBS) occurred among recipients of the swine influenza vaccine in 1976-1977.> Guillain-Barre syndrome remains the most frequent neurological condition> reported after influenza vaccination to the Vaccine Adverse Events Reporting> System (VAERS) since its inception in 1990. OBJECTIVE: To evaluate trends of> reports to VAERS of GBS following influenza vaccination in adults. DESIGN,> SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous reporting> system for adverse events following vaccination. Reports of GBS in persons> 18 years or older following influenza vaccination were evaluated for each> influenza season from July 1, 1990, through June 30, 2003. The number of> people vaccinated was estimated from the National Health Interview Survey> and US census data. Beginning in 1994, active follow-up was conducted to> verify GBS diagnosis and obtain other clinical details. MAIN OUTCOME> MEASURE: Reporting rates of GBS following influenza vaccination over time.> RESULTS: From July 1990 through June 2003, VAERS received 501 reports of GBS> following influenza vaccination in adults. The median onset interval (13> days) was longer than that of non-GBS reports of adverse events after> influenza vaccine (1 day) (P<.001). The annual reporting rate decreased> 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to 0.04 in> 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of reports.> Preceding illness within 4 weeks of vaccination was identified in 24% of> reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting rates of GBS> after influenza vaccination decreased. The long onset interval and low> prevalence of other preexisting illnesses are consistent with a possible> causal association between GBS and influenza vaccine. These findings require> additional research, which can lead to a fuller understanding of the causes> of GBS and its possible relationship with influenza vaccine.> > PMID: 15562126 [PubMed - indexed for MEDLINE]> > > > ---> > > > > Influenza vaccination and Guillain Barre syndrome small star, filled.> > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Geier+ MR%22%5BAuthor% 5D> Geier MR, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Geier+ DA%22%5BAuthor% 5D> Geier DA, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Zahalsky +AC%22%5BAuthor% 5D> Zahalsky AC. > > The Genetic Centers of America, 14 Redgate Court, Silver Spring, MD 20905,> USA. mgeier@... <mgeier@...>> > Acute and severe Guillain Barre Syndrome (GBS) cases reported following> influenza vaccine to the Vaccine Adverse Events Reporting System (VAERS)> database from 1991 through 1999 were examined. Endotoxin concentrations were> measured using the Limulus amebocyte lysate assay in influenza vaccines.> There were a total of 382 cases of GBS reported to the VAERS database> following influenza vaccination (male/female ratio, 1.2). The median onset> of GBS following influenza vaccine was 12 days (interquartile range, 7 days> to 21 days). There was an increased risk of acute GBS (relative risk, 4.3;> 95% confidence interval, 3.0 to 6.4) and severe GBS (relative risk, 8.5; 95%> confidence interval, 3.7 to 18.9) in comparison to an adult> tetanus-diphtheria (Td) vaccine control group. There were maximums in the> incidence of GBS following influenza vaccine that occurred approximately> every third year (1993, 1996, and 1998) and statistically significant> variation in the incidence of GBS among different influenza manufacturers.> Influenza vaccines contained from a 125- to a 1250-fold increase in> endotoxin concentrations in comparison to an adult Td vaccine control and> endotoxin concentrations varied up to 10-fold among different lots and> manufacturers of influenza vaccine. The biologic mechanism for GBS following> influenza vaccine may involve the synergistic effects of endotoxin and> vaccine-induced autoimmunity. There were minimal potential reporting biases> in the data reported to the VAERS database in this study. Patients should> make an informed consent decision on whether to take this optional vaccine> based upon its safety and efficacy and physicians should vigilantly report> GBS following influenza vaccination to the VAERS in the United States so> that continued evaluation of the safety of influenza vaccine may be> undertaken.> > PMID: 12763480 [PubMed - indexed for MEDLINE]> > > > Qadoshyah > <http://www.geocitie s.com/dsinfo05/ home.html>>__________________________________________________ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 19, 2006 Report Share Posted November 19, 2006 Hi Carol, Thank you so much. Obviously, we have a bit of stress right now with the upcoming surgery. I thought that maybe the insert was inaccurate and we'd really need to see current data. Jack seems to be really healthy. He's is 10mos. old and would need two shots. He reacted to his first round of baby shots --I think there were 6 given in all. Big mistake. I am pleased that he seems okay now. He pretty much slept for 48 hours and had difficulty wakening him to eat. Which just freaks the new mommy with a heart defect baby out??!! So, I told the drs. --too bad--we will immunize really slowly. One at a time. Jack surgery is in 10 days. I only had about four weeks to have gotten the flu shot. I have not really known how to make the decision--is it necessary or not? y'know. Of course, I don't want my son to get the flu. What do you think of the info. from the British Med Journal that was posted a few days ago? It questioned the effectiveness of the shot. We are not donating our own blood. His surgeon discouraged this--I did ask. She was concerned that it would make it harder for him later if he ever needed a transplant from one of us. Not a pleasant thought... I truly appreciate all of your insight--good to keep a balance. I know my brain has been emotionally preoccupied lately. Blessings, Z. > > > > Some interesting links to info about the flu vaccine - > > > > http://www.nccn. net/~wwithin/ flu.htm > > > > http://www.whale. to/vaccines/ flu.html - this one has package > inserts on it. > > > > > > http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1 > > <http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1 & id=116360837 0> > & id=1163608370 > > Flu Vaccine increases risk for neurological disorder > > planetc1.com- news@5:32 am PST <mailto:mail@ ...> email to the > > editor > > by Dorausch, DC > > planetc1.com news staff > > > > It is important to be aware of the risks involved when considering > taking > > any drug or vaccine or putting a drug or vaccine into a young ones > body. A > > new study has revealed that the flu vaccine is associated with an > increased > > risk of developing a debilitating neurological disorder known as > > Guillain-Barré syndrome. > > > > > > The debilitating nerve destroying syndrome affects about one in > 100,000 > > people each year. It results from the body's immune system > attacking parts > > of the nervous system, causing weakness or tingling that can > eventually lead > > to paralysis. Previous research had linked Guillain-Barré syndrome > to the > > flu vaccine, but researchers continue to look for more connections > between > > debilitating conditions and flu vaccines. > > > > > > According to the National Institute of Neurological Disorders and > Stroke, > > Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in which > the body's > > immune system attacks part of the peripheral nervous system. The > first > > symptoms of this disorder include varying degrees of weakness or > tingling > > sensations in the legs. In many instances the weakness and abnormal > > sensations spread to the arms and upper body. These symptoms can > increase in > > intensity until certain muscles cannot be used at all and, when > severe, the > > patient is almost totally paralyzed. > > > > > > The research comes from the University of Toronto. Researchers > studied > > residents in Ontario, where a flu vaccine immunization program was > started > > in 2000. All Ontario residents 6 months or older received a FREE > flu > > vaccine. Researchers looked into cases of hospitalization for > Guillain-Barré > > syndrome from 1993 to 2004. They then researched who had received > a flu > > vaccine and compared the individuals risk for the syndrome within > two to > > seven weeks after vaccination up to twenty to forty-three weeks > later. > > Researchers also compared the number of Guillain-Barré cases > before and > > after the immunization program began in 2000. > > > > > > Researchers discovered that Ontario residents were more likely to > be > > hospitalized for Guillain-Barré syndrome in the two to seven weeks > after > > being vaccinated than at forty-three weeks. It showed a small but > increased > > risk for the disease after vaccination. > > > > > > There has been a lot of discussion whether the flu vaccine is even > effective > > in preventing the flu. Add to that, the risk of developing > disabling nerve > > disorders, mercury toxicity (from shots containing thimerosal), as > well as > > other side effects, and you may wonder we one would even subject > themselves > > to the shot. One thing is for sure, the more people that get the > flu shot, > > the more data researchers will have to determine what disorders and > > conditions are caused by the shot. > > > > -- Doing a pubmed search for " Guillain-Barré syndrome > flu > > vaccine " yielded these results: > > > > > > A case of influenza vaccination induced Guillain Barre syndrome > with normal > > cerebrospinal fluid protein and improvement on treatment with > > corticosteroids. > > > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Eckert+ T%22%5BAuthor% 5D> Eckert T, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Bartels+ C%22%5BAuthor% 5D> Bartels C, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Mawrin+ C%22%5BAuthor% 5D> Mawrin C, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Feistner +H%22%5BAuthor% 5D> Feistner H, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Welte+ T%22%5BAuthor% 5D> Welte T. > > > > Department of Pneumology, Medical School of Hannover, Carl- Neuberg- > Str. 1, > > 30625 Hannover, Germany. > > > > We report a case of a 62-y-old male developing an influenza > vaccination > > induced Guillain Barre syndrome (GBS) showing all clinical and > > neuropathological symptoms of GBS except the characteristic > elevation of > > protein levels in the cerebrospinal fluid. The patient improved > under > > treatment with 100 mg prednisolone. In these cases the > administration of > > corticosteroids might be considered as a treatment option as they > might > > represent a subgroup of GBS with a different immunological > response pattern. > > > > PMID: 16138440 [PubMed - indexed for MEDLINE] > > > > > > > > ----- > > > > > > > > > > Guillain-Barre syndrome following influenza vaccination. > > > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Haber+ P%22%5BAuthor% 5D> Haber P, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22DeStefan o+F%22%5BAuthor% 5D> DeStefano F, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Angulo+ FJ%22%5BAuthor% 5D> Angulo FJ, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Iskander +J%22%5BAuthor% 5D> Iskander J, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Shadomy+ SV%22%5BAuthor% 5D> Shadomy SV, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Weintrau b+E%22%5BAuthor% 5D> Weintraub E, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Chen+ RT%22%5BAuthor% 5D> Chen RT. > > > > Immunization Safety Branch, Epidemiology and Surveillance > Division, National > > Immunization Program, Centers for Disease Control and Prevention, > Atlanta, > > Ga 30333, USA. PHaber@ > > > > CONTEXT: An unexplained increase in the risk of Guillain-Barre > syndrome > > (GBS) occurred among recipients of the swine influenza vaccine in > 1976-1977. > > Guillain-Barre syndrome remains the most frequent neurological > condition > > reported after influenza vaccination to the Vaccine Adverse Events > Reporting > > System (VAERS) since its inception in 1990. OBJECTIVE: To evaluate > trends of > > reports to VAERS of GBS following influenza vaccination in adults. > DESIGN, > > SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous > reporting > > system for adverse events following vaccination. Reports of GBS in > persons > > 18 years or older following influenza vaccination were evaluated > for each > > influenza season from July 1, 1990, through June 30, 2003. The > number of > > people vaccinated was estimated from the National Health Interview > Survey > > and US census data. Beginning in 1994, active follow-up was > conducted to > > verify GBS diagnosis and obtain other clinical details. MAIN > OUTCOME > > MEASURE: Reporting rates of GBS following influenza vaccination > over time. > > RESULTS: From July 1990 through June 2003, VAERS received 501 > reports of GBS > > following influenza vaccination in adults. The median onset > interval (13 > > days) was longer than that of non-GBS reports of adverse events > after > > influenza vaccine (1 day) (P<.001). The annual reporting rate > decreased > > 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to > 0.04 in > > 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of > reports. > > Preceding illness within 4 weeks of vaccination was identified in > 24% of > > reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting > rates of GBS > > after influenza vaccination decreased. The long onset interval and > low > > prevalence of other preexisting illnesses are consistent with a > possible > > causal association between GBS and influenza vaccine. These > findings require > > additional research, which can lead to a fuller understanding of > the causes > > of GBS and its possible relationship with influenza vaccine. > > > > PMID: 15562126 [PubMed - indexed for MEDLINE] > > > > > > > > --- > > > > > > > > > > Influenza vaccination and Guillain Barre syndrome small star, > filled. > > > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Geier+ MR%22%5BAuthor% 5D> Geier MR, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Geier+ DA%22%5BAuthor% 5D> Geier DA, > > > > * > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > db=pubmed & cmd= Search & itool= pu > > bmed_AbstractPlus & term=%22Zahalsky +AC%22%5BAuthor% 5D> Zahalsky AC. > > > > The Genetic Centers of America, 14 Redgate Court, Silver Spring, > MD 20905, > > USA. mgeier@ <mgeier@> > > > > Acute and severe Guillain Barre Syndrome (GBS) cases reported > following > > influenza vaccine to the Vaccine Adverse Events Reporting System > (VAERS) > > database from 1991 through 1999 were examined. Endotoxin > concentrations were > > measured using the Limulus amebocyte lysate assay in influenza > vaccines. > > There were a total of 382 cases of GBS reported to the VAERS > database > > following influenza vaccination (male/female ratio, 1.2). The > median onset > > of GBS following influenza vaccine was 12 days (interquartile > range, 7 days > > to 21 days). There was an increased risk of acute GBS (relative > risk, 4.3; > > 95% confidence interval, 3.0 to 6.4) and severe GBS (relative > risk, 8.5; 95% > > confidence interval, 3.7 to 18.9) in comparison to an adult > > tetanus-diphtheria (Td) vaccine control group. There were maximums > in the > > incidence of GBS following influenza vaccine that occurred > approximately > > every third year (1993, 1996, and 1998) and statistically > significant > > variation in the incidence of GBS among different influenza > manufacturers. > > Influenza vaccines contained from a 125- to a 1250-fold increase in > > endotoxin concentrations in comparison to an adult Td vaccine > control and > > endotoxin concentrations varied up to 10-fold among different lots > and > > manufacturers of influenza vaccine. The biologic mechanism for GBS > following > > influenza vaccine may involve the synergistic effects of endotoxin > and > > vaccine-induced autoimmunity. There were minimal potential > reporting biases > > in the data reported to the VAERS database in this study. Patients > should > > make an informed consent decision on whether to take this optional > vaccine > > based upon its safety and efficacy and physicians should > vigilantly report > > GBS following influenza vaccination to the VAERS in the United > States so > > that continued evaluation of the safety of influenza vaccine may be > > undertaken. > > > > PMID: 12763480 [PubMed - indexed for MEDLINE] > > > > > > > > Qadoshyah > > <http://www.geocitie s.com/dsinfo05/ home.html> > > > > > > > __________________________________________________ > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 20, 2006 Report Share Posted November 20, 2006 http://www.cochrane.org/reviews/en/ab004879.html Here is the site cited as the reference. As best I can tell no one there is calling for the halt of flu vaccinations. They are saying that the efficacy of vaccinating ALL children has yet to be proven with studies and there are few studies of flu vaccine helping healthy children under the age of 2. They are calling for more studies and go on to say how difficult it is to evaluate the efficacy of the killed flu vaccine and that the live nasal vaccine seems to work better. ( our kids can not have the live virus) at preventing flu. It's very interesting reading ..... they seem to be studying all types of illness and if the flu shot helps or not. They have determined that it does provoke an asthma attacks in children. Good to know since Drs recommend kids with asthma get a flu shot. Course they have not been able to determine how effective the shot is! " The new report entitled, "the prevention of seasonal influenza—policy versus evidence" examines the complex characteristics of seasonal influenza viruses (as opposed to pandemic viruses), which change their antigenic configuration from year to year as well as vary in prevalence – and so on their sensitivity to a vaccine. The report points out that influenza vaccine "performance" depends in part on the closeness of the match between forecasted circulating influenza viruses and the actual viruses selected for that influenza season's vaccine to act against. When the influenza viruses chosen for the vaccine closely resemble the circulating viruses in a given year, the vaccine is more protective. Another very important component is the amount of influenza circulating: the higher the circulation the higher the effectiveness of the vaccines. Unfortunately no one can predict this and the amount of "flu-like illness" circulating is no predictor as it is different from real influenza. According to the report, a major problem with evaluating influenza vaccine performance is potential confusion between respiratory infections caused by influenza viruses and those caused by other viruses (the ‘flu’). Misdiagnosis of influenza in patients with respiratory infections caused by other viruses can lead to a gross overestimation of the true impact of influenza on death and illness from respiratory infections in a given influenza season" http://www.cochrane.org/consumers/happenings.htm Again, I suggest going to the source and reading. They are not saying the vaccine never works or there is no basis to say it doesn't work. They are saying there is NOT enough unbiased studies as to how effective it is in healthy children and the elderly. I could not find much regarding effectivness in unhealthy children, such as cardiac kids..... there was a study on kids with CF that stated it DID help prevent flu, but nothing studied regarding the protection of lung function in CF. I don't have time to look more right now- conference day at school. :-) This one regarding the effectiveness of Oscillococcinum came up though and thought it was interesting- Abstract Background Influenza is a highly infectious viral disease that is particularly common in the winter months. Oscillococcinum is a patented, commercially available homoeopathic medicine. The rationale for its use in influenza comes from the homoeopathic principle of 'let like be cured by like'. This medicine is manufactured from wild duck heart and liver, which are said to be reservoirs for influenza viruses. Objectives To determine whether homoeopathic Oscillococcinum or similar medicines are more effective than placebo in the prevention and treatment of influenza and influenza-like syndromes. Search strategy We updated the electronic searches on the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006); MEDLINE (January 1966 to February 2006) and EMBASE (1980 to February 2006). The manufacturers of Oscillococcinum were contacted for information. Selection criteria Placebo-controlled trials of Oscillococcinum or homeopathically-prepared influenza virus, influenza vaccine or avian liver in the prevention and treatment of influenza and influenza-like syndromes. Data collection and analysis Two authors extracted data and assessed methodological quality independently. Main results Seven studies were included in the review, three prevention trials (number of participants (n) = 2265) and four treatment trials (n = 1194). Only two studies reported sufficient information to complete data extraction fully. There was no evidence that homoeopathic treatment can prevent influenza-like syndrome (relative risk (RR) 0.64, 95% confidence interval (CI) 0.28 to 1.43). Oscillococcinum treatment reduced the length of influenza illness by 0.28 days (95% CI 0.50 to 0.06). Oscillococcinum also increased the chances that a patient considered treatment to be effective (RR 1.08; 95% CI 1.17 to 1.00). Authors' conclusions Though promising, the data were not strong enough to make a general recommendation to use Oscillococcinum for first-line treatment of influenza and influenza-like syndromes. Further research is warranted but the required sample sizes are large. Current evidence does not support a preventative effect of Oscillococcinum-like homeopathic medicines in influenza and influenza-like syndromes. The entity calling for the halt of the flu vaccine is a well known anti-vaccine group, so consider the source. It's not like a medical entity is calling for it's halt. http://www.909shot.com/PressReleases/pr1031flu.htm despite it's official sounding name. is 6 and we still are not done with our vaccinations! She needs one more MMR and then we are done! So I am a big advocate of going very slowly. We did a select few vaccines before her repair. Hep and .... hhmm.. the brain is not working this morning.... the one easily passed around in hosptials and daycares in younger kids....want to say parvo virus, but that is the wrong speices :-) Someone will know...she couldn't have the RSV shot pre-op either. She was breastfed and while in the hospital I licked her a LOT. <g> Esp on her hands and around her face to be sure and pick up anything lurking there before it got to her. Seemed to work. Take antibacterial wipes with you and wipe down all the bars, tables etc. I did a lot of cleaning in the hospital. Make them leave a stethoscope in the room used only for him, or make them wash down any they use with alcholol or something. Watch nurses to make they wash their hands!!! Some don't... make them wear masks, gloves and a gown too. They are walking germ carriers... they can't help it. We were lucky to have our repair in June and we just cut ourselves off from everyone for about a year to avoid germs. She caught one slight cold pre-op and let me tell you it was NOT something I would want to do again. Scary....and luckily it was just a little garden varieity bug that everyone elses sailed through. I know the feeling of being preoccupied pre-op.... the brain can only handle so much at one time. Soon this will all be a distant memory!! I have effectively blocked it all out now. :-) Took a while... we don't even commemorate the anniversery of her repair. Would rather not remember all that stress, esp since we may have another surgery in the future. I prefer to enjoy the day untainted. ;-) Carol in IL Mom to seven including , 6 with TOF, AVcanal, GERD, LS, Asthma, subglottal stenosis, chronic constipation ( cured now ) and DS. My problem is not how I look. It's how you see me. Re: The Flu Vaccine Hi Carol,Thank you so much. Obviously, we have a bit of stress right now with the upcoming surgery. I thought that maybe the insert was inaccurate and we'd really need to see current data. Jack seems to be really healthy. He's is 10mos. old and would need two shots. He reacted to his first round of baby shots --I think there were 6 given in all. Big mistake. I am pleased that he seems okay now. He pretty much slept for 48 hours and had difficulty wakening him to eat. Which just freaks the new mommy with a heart defect baby out??!! So, I told the drs. --too bad--we will immunize really slowly. One at a time. Jack surgery is in 10 days. I only had about four weeks to have gotten the flu shot. I have not really known how to make the decision--is it necessary or not? y'know. Of course, I don't want my son to get the flu. What do you think of the info. from the British Med Journal that was posted a few days ago? It questioned the effectiveness of the shot. We are not donating our own blood. His surgeon discouraged this--I did ask. She was concerned that it would make it harder for him later if he ever needed a transplant from one of us. Not a pleasant thought...I truly appreciate all of your insight--good to keep a balance. I know my brain has been emotionally preoccupied lately.Blessings, Z.> >> > Some interesting links to info about the flu vaccine - > > > > http://www.nccn. net/~wwithin/ flu.htm> > > > http://www.whale. to/vaccines/ flu.html - this one has package > inserts on it.> > > > > > http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1> > <http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1 & id=116360837 0> > & id=1163608370> > Flu Vaccine increases risk for neurological disorder> > planetc1.com- news@5:32 am PST <mailto:mail@ ...> email to the> > editor> > by Dorausch, DC> > planetc1.com news staff > > > > It is important to be aware of the risks involved when considering > taking> > any drug or vaccine or putting a drug or vaccine into a young ones > body. A> > new study has revealed that the flu vaccine is associated with an > increased> > risk of developing a debilitating neurological disorder known as> > Guillain-Barré syndrome. > > > > > > The debilitating nerve destroying syndrome affects about one in > 100,000> > people each year. It results from the body's immune system > attacking parts> > of the nervous system, causing weakness or tingling that can > eventually lead> > to paralysis. Previous research had linked Guillain-Barré syndrome > to the> > flu vaccine, but researchers continue to look for more connections > between> > debilitating conditions and flu vaccines. > > > > > > According to the National Institute of Neurological Disorders and > Stroke,> > Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in which > the body's> > immune system attacks part of the peripheral nervous system. The > first> > symptoms of this disorder include varying degrees of weakness or > tingling> > sensations in the legs. In many instances the weakness and abnormal> > sensations spread to the arms and upper body. These symptoms can > increase in> > intensity until certain muscles cannot be used at all and, when > severe, the> > patient is almost totally paralyzed. > > > > > > The research comes from the University of Toronto. Researchers > studied> > residents in Ontario, where a flu vaccine immunization program was > started> > in 2000. All Ontario residents 6 months or older received a FREE > flu> > vaccine. Researchers looked into cases of hospitalization for > Guillain-Barré> > syndrome from 1993 to 2004. They then researched who had received > a flu> > vaccine and compared the individuals risk for the syndrome within > two to> > seven weeks after vaccination up to twenty to forty-three weeks > later.> > Researchers also compared the number of Guillain-Barré cases > before and> > after the immunization program began in 2000. > > > > > > Researchers discovered that Ontario residents were more likely to > be> > hospitalized for Guillain-Barré syndrome in the two to seven weeks > after> > being vaccinated than at forty-three weeks. It showed a small but > increased> > risk for the disease after vaccination. > > > > > > There has been a lot of discussion whether the flu vaccine is even > effective> > in preventing the flu. Add to that, the risk of developing > disabling nerve> > disorders, mercury toxicity (from shots containing thimerosal), as > well as> > other side effects, and you may wonder we one would even subject > themselves> > to the shot. One thing is for sure, the more people that get the > flu shot,> > the more data researchers will have to determine what disorders and> > conditions are caused by the shot.> > > > -- Doing a pubmed search for "Guillain-Barré syndrome > flu> > vaccine" yielded these results:> > > > > > A case of influenza vaccination induced Guillain Barre syndrome > with normal> > cerebrospinal fluid protein and improvement on treatment with> > corticosteroids.> > > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Eckert+ T%22%5BAuthor% 5D> Eckert T, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Bartels+ C%22%5BAuthor% 5D> Bartels C, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Mawrin+ C%22%5BAuthor% 5D> Mawrin C, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Feistner +H%22%5BAuthor% 5D> Feistner H, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Welte+ T%22%5BAuthor% 5D> Welte T. > > > > Department of Pneumology, Medical School of Hannover, Carl-Neuberg-> Str. 1,> > 30625 Hannover, Germany.> > > > We report a case of a 62-y-old male developing an influenza > vaccination> > induced Guillain Barre syndrome (GBS) showing all clinical and> > neuropathological symptoms of GBS except the characteristic > elevation of> > protein levels in the cerebrospinal fluid. The patient improved > under> > treatment with 100 mg prednisolone. In these cases the > administration of> > corticosteroids might be considered as a treatment option as they > might> > represent a subgroup of GBS with a different immunological > response pattern.> > > > PMID: 16138440 [PubMed - indexed for MEDLINE]> > > > > > > > -----> > > > > > > > > > Guillain-Barre syndrome following influenza vaccination.> > > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Haber+ P%22%5BAuthor% 5D> Haber P, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22DeStefan o+F%22%5BAuthor% 5D> DeStefano F, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Angulo+ FJ%22%5BAuthor% 5D> Angulo FJ, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Iskander +J%22%5BAuthor% 5D> Iskander J, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Shadomy+ SV%22%5BAuthor% 5D> Shadomy SV, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Weintrau b+E%22%5BAuthor% 5D> Weintraub E, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Chen+ RT%22%5BAuthor% 5D> Chen RT. > > > > Immunization Safety Branch, Epidemiology and Surveillance > Division, National> > Immunization Program, Centers for Disease Control and Prevention, > Atlanta,> > Ga 30333, USA. PHaber@> > > > CONTEXT: An unexplained increase in the risk of Guillain-Barre > syndrome> > (GBS) occurred among recipients of the swine influenza vaccine in > 1976-1977.> > Guillain-Barre syndrome remains the most frequent neurological > condition> > reported after influenza vaccination to the Vaccine Adverse Events > Reporting> > System (VAERS) since its inception in 1990. OBJECTIVE: To evaluate > trends of> > reports to VAERS of GBS following influenza vaccination in adults. > DESIGN,> > SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous > reporting> > system for adverse events following vaccination. Reports of GBS in > persons> > 18 years or older following influenza vaccination were evaluated > for each> > influenza season from July 1, 1990, through June 30, 2003. The > number of> > people vaccinated was estimated from the National Health Interview > Survey> > and US census data. Beginning in 1994, active follow-up was > conducted to> > verify GBS diagnosis and obtain other clinical details. MAIN > OUTCOME> > MEASURE: Reporting rates of GBS following influenza vaccination > over time.> > RESULTS: From July 1990 through June 2003, VAERS received 501 > reports of GBS> > following influenza vaccination in adults. The median onset > interval (13> > days) was longer than that of non-GBS reports of adverse events > after> > influenza vaccine (1 day) (P<.001). The annual reporting rate > decreased> > 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to > 0.04 in> > 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of > reports.> > Preceding illness within 4 weeks of vaccination was identified in > 24% of> > reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting > rates of GBS> > after influenza vaccination decreased. The long onset interval and > low> > prevalence of other preexisting illnesses are consistent with a > possible> > causal association between GBS and influenza vaccine. These > findings require> > additional research, which can lead to a fuller understanding of > the causes> > of GBS and its possible relationship with influenza vaccine.> > > > PMID: 15562126 [PubMed - indexed for MEDLINE]> > > > > > > > ---> > > > > > > > > > Influenza vaccination and Guillain Barre syndrome small star, > filled.> > > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Geier+ MR%22%5BAuthor% 5D> Geier MR, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Geier+ DA%22%5BAuthor% 5D> Geier DA, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Zahalsky +AC%22%5BAuthor% 5D> Zahalsky AC. > > > > The Genetic Centers of America, 14 Redgate Court, Silver Spring, > MD 20905,> > USA. mgeier@ <mgeier@>> > > > Acute and severe Guillain Barre Syndrome (GBS) cases reported > following> > influenza vaccine to the Vaccine Adverse Events Reporting System > (VAERS)> > database from 1991 through 1999 were examined. Endotoxin > concentrations were> > measured using the Limulus amebocyte lysate assay in influenza > vaccines.> > There were a total of 382 cases of GBS reported to the VAERS > database> > following influenza vaccination (male/female ratio, 1.2). The > median onset> > of GBS following influenza vaccine was 12 days (interquartile > range, 7 days> > to 21 days). There was an increased risk of acute GBS (relative > risk, 4.3;> > 95% confidence interval, 3.0 to 6.4) and severe GBS (relative > risk, 8.5; 95%> > confidence interval, 3.7 to 18.9) in comparison to an adult> > tetanus-diphtheria (Td) vaccine control group. There were maximums > in the> > incidence of GBS following influenza vaccine that occurred > approximately> > every third year (1993, 1996, and 1998) and statistically > significant> > variation in the incidence of GBS among different influenza > manufacturers.> > Influenza vaccines contained from a 125- to a 1250-fold increase in> > endotoxin concentrations in comparison to an adult Td vaccine > control and> > endotoxin concentrations varied up to 10-fold among different lots > and> > manufacturers of influenza vaccine. The biologic mechanism for GBS > following> > influenza vaccine may involve the synergistic effects of endotoxin > and> > vaccine-induced autoimmunity. There were minimal potential > reporting biases> > in the data reported to the VAERS database in this study. Patients > should> > make an informed consent decision on whether to take this optional > vaccine> > based upon its safety and efficacy and physicians should > vigilantly report> > GBS following influenza vaccination to the VAERS in the United > States so> > that continued evaluation of the safety of influenza vaccine may be> > undertaken.> > > > PMID: 12763480 [PubMed - indexed for MEDLINE]> > > > > > > > Qadoshyah > > <http://www.geocitie s.com/dsinfo05/ home.html>> >> > > > > ____________ _________ _________ _________ _________ __> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 20, 2006 Report Share Posted November 20, 2006 Thank you Carol! You're a dear!! Yesterday was the day I went around the corner. hee hee I don't know when I'll be back--after the surgery, I'm sure. Z. > > > > > > Some interesting links to info about the flu vaccine - > > > > > > http://www.nccn. net/~wwithin/ flu.htm > > > > > > http://www.whale. to/vaccines/ flu.html - this one has package > > inserts on it. > > > > > > > > > http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1 > > > <http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1 & id=116360837 0> > > & id=1163608370 > > > Flu Vaccine increases risk for neurological disorder > > > planetc1.com- news@5:32 am PST <mailto:mail@ ...> email to the > > > editor > > > by Dorausch, DC > > > planetc1.com news staff > > > > > > It is important to be aware of the risks involved when > considering > > taking > > > any drug or vaccine or putting a drug or vaccine into a young > ones > > body. A > > > new study has revealed that the flu vaccine is associated with > an > > increased > > > risk of developing a debilitating neurological disorder known as > > > Guillain-Barré syndrome. > > > > > > > > > The debilitating nerve destroying syndrome affects about one in > > 100,000 > > > people each year. It results from the body's immune system > > attacking parts > > > of the nervous system, causing weakness or tingling that can > > eventually lead > > > to paralysis. Previous research had linked Guillain-Barré > syndrome > > to the > > > flu vaccine, but researchers continue to look for more > connections > > between > > > debilitating conditions and flu vaccines. > > > > > > > > > According to the National Institute of Neurological Disorders > and > > Stroke, > > > Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in > which > > the body's > > > immune system attacks part of the peripheral nervous system. The > > first > > > symptoms of this disorder include varying degrees of weakness or > > tingling > > > sensations in the legs. In many instances the weakness and > abnormal > > > sensations spread to the arms and upper body. These symptoms can > > increase in > > > intensity until certain muscles cannot be used at all and, when > > severe, the > > > patient is almost totally paralyzed. > > > > > > > > > The research comes from the University of Toronto. Researchers > > studied > > > residents in Ontario, where a flu vaccine immunization program > was > > started > > > in 2000. All Ontario residents 6 months or older received a FREE > > flu > > > vaccine. Researchers looked into cases of hospitalization for > > Guillain-Barré > > > syndrome from 1993 to 2004. They then researched who had > received > > a flu > > > vaccine and compared the individuals risk for the syndrome > within > > two to > > > seven weeks after vaccination up to twenty to forty-three weeks > > later. > > > Researchers also compared the number of Guillain-Barré cases > > before and > > > after the immunization program began in 2000. > > > > > > > > > Researchers discovered that Ontario residents were more likely > to > > be > > > hospitalized for Guillain-Barré syndrome in the two to seven > weeks > > after > > > being vaccinated than at forty-three weeks. It showed a small > but > > increased > > > risk for the disease after vaccination. > > > > > > > > > There has been a lot of discussion whether the flu vaccine is > even > > effective > > > in preventing the flu. Add to that, the risk of developing > > disabling nerve > > > disorders, mercury toxicity (from shots containing thimerosal), > as > > well as > > > other side effects, and you may wonder we one would even subject > > themselves > > > to the shot. One thing is for sure, the more people that get the > > flu shot, > > > the more data researchers will have to determine what disorders > and > > > conditions are caused by the shot. > > > > > > -- Doing a pubmed search for " Guillain-Barré syndrome > > flu > > > vaccine " yielded these results: > > > > > > > > > A case of influenza vaccination induced Guillain Barre syndrome > > with normal > > > cerebrospinal fluid protein and improvement on treatment with > > > corticosteroids. > > > > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Eckert+ T%22%5BAuthor% 5D> Eckert T, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Bartels+ C%22%5BAuthor% 5D> Bartels > C, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Mawrin+ C%22%5BAuthor% 5D> Mawrin C, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Feistner +H%22%5BAuthor% 5D> Feistner > H, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Welte+ T%22%5BAuthor% 5D> Welte T. > > > > > > Department of Pneumology, Medical School of Hannover, Carl- > Neuberg- > > Str. 1, > > > 30625 Hannover, Germany. > > > > > > We report a case of a 62-y-old male developing an influenza > > vaccination > > > induced Guillain Barre syndrome (GBS) showing all clinical and > > > neuropathological symptoms of GBS except the characteristic > > elevation of > > > protein levels in the cerebrospinal fluid. The patient improved > > under > > > treatment with 100 mg prednisolone. In these cases the > > administration of > > > corticosteroids might be considered as a treatment option as > they > > might > > > represent a subgroup of GBS with a different immunological > > response pattern. > > > > > > PMID: 16138440 [PubMed - indexed for MEDLINE] > > > > > > > > > > > > ----- > > > > > > > > > > > > > > > Guillain-Barre syndrome following influenza vaccination. > > > > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Haber+ P%22%5BAuthor% 5D> Haber P, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22DeStefan o+F%22%5BAuthor% 5D> > DeStefano F, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Angulo+ FJ%22%5BAuthor% 5D> Angulo > FJ, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Iskander +J%22%5BAuthor% 5D> Iskander > J, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Shadomy+ SV%22%5BAuthor% 5D> Shadomy > SV, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Weintrau b+E%22%5BAuthor% 5D> > Weintraub E, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Chen+ RT%22%5BAuthor% 5D> Chen RT. > > > > > > Immunization Safety Branch, Epidemiology and Surveillance > > Division, National > > > Immunization Program, Centers for Disease Control and > Prevention, > > Atlanta, > > > Ga 30333, USA. PHaber@ > > > > > > CONTEXT: An unexplained increase in the risk of Guillain-Barre > > syndrome > > > (GBS) occurred among recipients of the swine influenza vaccine > in > > 1976-1977. > > > Guillain-Barre syndrome remains the most frequent neurological > > condition > > > reported after influenza vaccination to the Vaccine Adverse > Events > > Reporting > > > System (VAERS) since its inception in 1990. OBJECTIVE: To > evaluate > > trends of > > > reports to VAERS of GBS following influenza vaccination in > adults. > > DESIGN, > > > SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous > > reporting > > > system for adverse events following vaccination. Reports of GBS > in > > persons > > > 18 years or older following influenza vaccination were evaluated > > for each > > > influenza season from July 1, 1990, through June 30, 2003. The > > number of > > > people vaccinated was estimated from the National Health > Interview > > Survey > > > and US census data. Beginning in 1994, active follow-up was > > conducted to > > > verify GBS diagnosis and obtain other clinical details. MAIN > > OUTCOME > > > MEASURE: Reporting rates of GBS following influenza vaccination > > over time. > > > RESULTS: From July 1990 through June 2003, VAERS received 501 > > reports of GBS > > > following influenza vaccination in adults. The median onset > > interval (13 > > > days) was longer than that of non-GBS reports of adverse events > > after > > > influenza vaccine (1 day) (P<.001). The annual reporting rate > > decreased > > > 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to > > 0.04 in > > > 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of > > reports. > > > Preceding illness within 4 weeks of vaccination was identified > in > > 24% of > > > reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting > > rates of GBS > > > after influenza vaccination decreased. The long onset interval > and > > low > > > prevalence of other preexisting illnesses are consistent with a > > possible > > > causal association between GBS and influenza vaccine. These > > findings require > > > additional research, which can lead to a fuller understanding of > > the causes > > > of GBS and its possible relationship with influenza vaccine. > > > > > > PMID: 15562126 [PubMed - indexed for MEDLINE] > > > > > > > > > > > > --- > > > > > > > > > > > > > > > Influenza vaccination and Guillain Barre syndrome small star, > > filled. > > > > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Geier+ MR%22%5BAuthor% 5D> Geier MR, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Geier+ DA%22%5BAuthor% 5D> Geier DA, > > > > > > * > > > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi? > > db=pubmed & cmd= Search & itool= pu > > > bmed_AbstractPlus & term=%22Zahalsky +AC%22%5BAuthor% 5D> > Zahalsky AC. > > > > > > The Genetic Centers of America, 14 Redgate Court, Silver Spring, > > MD 20905, > > > USA. mgeier@ <mgeier@> > > > > > > Acute and severe Guillain Barre Syndrome (GBS) cases reported > > following > > > influenza vaccine to the Vaccine Adverse Events Reporting System > > (VAERS) > > > database from 1991 through 1999 were examined. Endotoxin > > concentrations were > > > measured using the Limulus amebocyte lysate assay in influenza > > vaccines. > > > There were a total of 382 cases of GBS reported to the VAERS > > database > > > following influenza vaccination (male/female ratio, 1.2). The > > median onset > > > of GBS following influenza vaccine was 12 days (interquartile > > range, 7 days > > > to 21 days). There was an increased risk of acute GBS (relative > > risk, 4.3; > > > 95% confidence interval, 3.0 to 6.4) and severe GBS (relative > > risk, 8.5; 95% > > > confidence interval, 3.7 to 18.9) in comparison to an adult > > > tetanus-diphtheria (Td) vaccine control group. There were > maximums > > in the > > > incidence of GBS following influenza vaccine that occurred > > approximately > > > every third year (1993, 1996, and 1998) and statistically > > significant > > > variation in the incidence of GBS among different influenza > > manufacturers. > > > Influenza vaccines contained from a 125- to a 1250-fold increase > in > > > endotoxin concentrations in comparison to an adult Td vaccine > > control and > > > endotoxin concentrations varied up to 10-fold among different > lots > > and > > > manufacturers of influenza vaccine. The biologic mechanism for > GBS > > following > > > influenza vaccine may involve the synergistic effects of > endotoxin > > and > > > vaccine-induced autoimmunity. There were minimal potential > > reporting biases > > > in the data reported to the VAERS database in this study. > Patients > > should > > > make an informed consent decision on whether to take this > optional > > vaccine > > > based upon its safety and efficacy and physicians should > > vigilantly report > > > GBS following influenza vaccination to the VAERS in the United > > States so > > > that continued evaluation of the safety of influenza vaccine may > be > > > undertaken. > > > > > > PMID: 12763480 [PubMed - indexed for MEDLINE] > > > > > > > > > > > > Qadoshyah > > > <http://www.geocitie s.com/dsinfo05/ home.html> > > > > > > > > > > > > > ____________ _________ _________ _________ _________ __ > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 20, 2006 Report Share Posted November 20, 2006 There's this study also. It was done in Canada - Incidence of influenza in Ontario following the Universal Influenza Immunization Campaign.University of Ottawa, Faculty of Health Sciences, 451 Smyth Road (3251D), Ottawa, Ont., Canada K1H 8M5. dgroll@...The purpose of this study was to determine whether the incidence of influenza in Ontario, Canada has decreased following the introduction of the Universal Influenza Immunization Campaign (UIIC) in 2000. All laboratory-confirmed influenza cases in Ontario, from January 1990 to August 2005 were analyzed using multitaper time series analysis. We found that there has not been a decrease in the mean monthly influenza rate following the introduction of the UIIC (109.5 (S.D. 20) versus 160 (S.D. 50.3) p>0.1). Despite increased vaccine distribution and financial resources towards promotion, the incidence of influenza in Ontario has not decreased following the introduction of the UIIC. Qadoshyah *Got Down Syndrome? www.gotdownsyndrome.net From: Down Syndrome Treatment [mailto:Down Syndrome Treatment ] On Behalf Of Carol in ILSent: Monday, November 20, 2006 6:48 AMDown Syndrome Treatment Subject: Re: Re: The Flu Vaccine http://www.cochrane.org/reviews/en/ab004879.html Here is the site cited as the reference. As best I can tell no one there is calling for the halt of flu vaccinations. They are saying that the efficacy of vaccinating ALL children has yet to be proven with studies and there are few studies of flu vaccine helping healthy children under the age of 2. They are calling for more studies and go on to say how difficult it is to evaluate the efficacy of the killed flu vaccine and that the live nasal vaccine seems to work better. ( our kids can not have the live virus) at preventing flu. It's very interesting reading ..... they seem to be studying all types of illness and if the flu shot helps or not. They have determined that it does provoke an asthma attacks in children. Good to know since Drs recommend kids with asthma get a flu shot. Course they have not been able to determine how effective the shot is! " The new report entitled, "the prevention of seasonal influenza—policy versus evidence" examines the complex characteristics of seasonal influenza viruses (as opposed to pandemic viruses), which change their antigenic configuration from year to year as well as vary in prevalence – and so on their sensitivity to a vaccine. The report points out that influenza vaccine "performance" depends in part on the closeness of the match between forecasted circulating influenza viruses and the actual viruses selected for that influenza season's vaccine to act against. When the influenza viruses chosen for the vaccine closely resemble the circulating viruses in a given year, the vaccine is more protective. Another very important component is the amount of influenza circulating: the higher the circulation the higher the effectiveness of the vaccines. Unfortunately no one can predict this and the amount of "flu-like illness" circulating is no predictor as it is different from real influenza. According to the report, a major problem with evaluating influenza vaccine performance is potential confusion between respiratory infections caused by influenza viruses and those caused by other viruses (the ‘flu’). Misdiagnosis of influenza in patients with respiratory infections caused by other viruses can lead to a gross overestimation of the true impact of influenza on death and illness from respiratory infections in a given influenza season" http://www.cochrane.org/consumers/happenings.htm Again, I suggest going to the source and reading. They are not saying the vaccine never works or there is no basis to say it doesn't work. They are saying there is NOT enough unbiased studies as to how effective it is in healthy children and the elderly. I could not find much regarding effectivness in unhealthy children, such as cardiac kids..... there was a study on kids with CF that stated it DID help prevent flu, but nothing studied regarding the protection of lung function in CF. I don't have time to look more right now- conference day at school. :-) This one regarding the effectiveness of Oscillococcinum came up though and thought it was interesting- Abstract Background Influenza is a highly infectious viral disease that is particularly common in the winter months. Oscillococcinum is a patented, commercially available homoeopathic medicine. The rationale for its use in influenza comes from the homoeopathic principle of 'let like be cured by like'. This medicine is manufactured from wild duck heart and liver, which are said to be reservoirs for influenza viruses. Objectives To determine whether homoeopathic Oscillococcinum or similar medicines are more effective than placebo in the prevention and treatment of influenza and influenza-like syndromes. Search strategy We updated the electronic searches on the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006); MEDLINE (January 1966 to February 2006) and EMBASE (1980 to February 2006). The manufacturers of Oscillococcinum were contacted for information. Selection criteria Placebo-controlled trials of Oscillococcinum or homeopathically-prepared influenza virus, influenza vaccine or avian liver in the prevention and treatment of influenza and influenza-like syndromes. Data collection and analysis Two authors extracted data and assessed methodological quality independently. Main results Seven studies were included in the review, three prevention trials (number of participants (n) = 2265) and four treatment trials (n = 1194). Only two studies reported sufficient information to complete data extraction fully. There was no evidence that homoeopathic treatment can prevent influenza-like syndrome (relative risk (RR) 0.64, 95% confidence interval (CI) 0.28 to 1.43). Oscillococcinum treatment reduced the length of influenza illness by 0.28 days (95% CI 0.50 to 0.06). Oscillococcinum also increased the chances that a patient considered treatment to be effective (RR 1.08; 95% CI 1.17 to 1.00). Authors' conclusions Though promising, the data were not strong enough to make a general recommendation to use Oscillococcinum for first-line treatment of influenza and influenza-like syndromes. Further research is warranted but the required sample sizes are large. Current evidence does not support a preventative effect of Oscillococcinum-like homeopathic medicines in influenza and influenza-like syndromes. The entity calling for the halt of the flu vaccine is a well known anti-vaccine group, so consider the source. It's not like a medical entity is calling for it's halt. http://www.909shot.com/PressReleases/pr1031flu.htm despite it's official sounding name. is 6 and we still are not done with our vaccinations! She needs one more MMR and then we are done! So I am a big advocate of going very slowly. We did a select few vaccines before her repair. Hep and .... hhmm.. the brain is not working this morning.... the one easily passed around in hosptials and daycares in younger kids....want to say parvo virus, but that is the wrong speices :-) Someone will know...she couldn't have the RSV shot pre-op either. She was breastfed and while in the hospital I licked her a LOT. <g> Esp on her hands and around her face to be sure and pick up anything lurking there before it got to her. Seemed to work. Take antibacterial wipes with you and wipe down all the bars, tables etc. I did a lot of cleaning in the hospital. Make them leave a stethoscope in the room used only for him, or make them wash down any they use with alcholol or something. Watch nurses to make they wash their hands!!! Some don't... make them wear masks, gloves and a gown too. They are walking germ carriers... they can't help it. We were lucky to have our repair in June and we just cut ourselves off from everyone for about a year to avoid germs. She caught one slight cold pre-op and let me tell you it was NOT something I would want to do again. Scary....and luckily it was just a little garden varieity bug that everyone elses sailed through. I know the feeling of being preoccupied pre-op.... the brain can only handle so much at one time. Soon this will all be a distant memory!! I have effectively blocked it all out now. :-) Took a while... we don't even commemorate the anniversery of her repair. Would rather not remember all that stress, esp since we may have another surgery in the future. I prefer to enjoy the day untainted. ;-) Carol in IL Mom to seven including , 6 with TOF, AVcanal, GERD, LS, Asthma, subglottal stenosis, chronic constipation ( cured now ) and DS. My problem is not how I look. It's how you see me. Re: The Flu Vaccine Hi Carol,Thank you so much. Obviously, we have a bit of stress right now with the upcoming surgery. I thought that maybe the insert was inaccurate and we'd really need to see current data. Jack seems to be really healthy. He's is 10mos. old and would need two shots. He reacted to his first round of baby shots --I think there were 6 given in all. Big mistake. I am pleased that he seems okay now. He pretty much slept for 48 hours and had difficulty wakening him to eat. Which just freaks the new mommy with a heart defect baby out??!! So, I told the drs. --too bad--we will immunize really slowly. One at a time. Jack surgery is in 10 days. I only had about four weeks to have gotten the flu shot. I have not really known how to make the decision--is it necessary or not? y'know. Of course, I don't want my son to get the flu. What do you think of the info. from the British Med Journal that was posted a few days ago? It questioned the effectiveness of the shot. We are not donating our own blood. His surgeon discouraged this--I did ask. She was concerned that it would make it harder for him later if he ever needed a transplant from one of us. Not a pleasant thought...I truly appreciate all of your insight--good to keep a balance. I know my brain has been emotionally preoccupied lately.Blessings, Z.> >> > Some interesting links to info about the flu vaccine - > > > > http://www.nccn. net/~wwithin/ flu.htm> > > > http://www.whale. to/vaccines/ flu.html - this one has package > inserts on it.> > > > > > http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1> > <http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1 & id=116360837 0> > & id=1163608370> > Flu Vaccine increases risk for neurological disorder> > planetc1.com- news@5:32 am PST <mailto:mail@ ...> email to the> > editor> > by Dorausch, DC> > planetc1.com news staff > > > > It is important to be aware of the risks involved when considering > taking> > any drug or vaccine or putting a drug or vaccine into a young ones > body. A> > new study has revealed that the flu vaccine is associated with an > increased> > risk of developing a debilitating neurological disorder known as> > Guillain-Barré syndrome. > > > > > > The debilitating nerve destroying syndrome affects about one in > 100,000> > people each year. It results from the body's immune system > attacking parts> > of the nervous system, causing weakness or tingling that can > eventually lead> > to paralysis. Previous research had linked Guillain-Barré syndrome > to the> > flu vaccine, but researchers continue to look for more connections > between> > debilitating conditions and flu vaccines. > > > > > > According to the National Institute of Neurological Disorders and > Stroke,> > Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in which > the body's> > immune system attacks part of the peripheral nervous system. The > first> > symptoms of this disorder include varying degrees of weakness or > tingling> > sensations in the legs. In many instances the weakness and abnormal> > sensations spread to the arms and upper body. These symptoms can > increase in> > intensity until certain muscles cannot be used at all and, when > severe, the> > patient is almost totally paralyzed. > > > > > > The research comes from the University of Toronto. Researchers > studied> > residents in Ontario, where a flu vaccine immunization program was > started> > in 2000. All Ontario residents 6 months or older received a FREE > flu> > vaccine. Researchers looked into cases of hospitalization for > Guillain-Barré> > syndrome from 1993 to 2004. They then researched who had received > a flu> > vaccine and compared the individuals risk for the syndrome within > two to> > seven weeks after vaccination up to twenty to forty-three weeks > later.> > Researchers also compared the number of Guillain-Barré cases > before and> > after the immunization program began in 2000. > > > > > > Researchers discovered that Ontario residents were more likely to > be> > hospitalized for Guillain-Barré syndrome in the two to seven weeks > after> > being vaccinated than at forty-three weeks. It showed a small but > increased> > risk for the disease after vaccination. > > > > > > There has been a lot of discussion whether the flu vaccine is even > effective> > in preventing the flu. Add to that, the risk of developing > disabling nerve> > disorders, mercury toxicity (from shots containing thimerosal), as > well as> > other side effects, and you may wonder we one would even subject > themselves> > to the shot. One thing is for sure, the more people that get the > flu shot,> > the more data researchers will have to determine what disorders and> > conditions are caused by the shot.> > > > -- Doing a pubmed search for "Guillain-Barré syndrome > flu> > vaccine" yielded these results:> > > > > > A case of influenza vaccination induced Guillain Barre syndrome > with normal> > cerebrospinal fluid protein and improvement on treatment with> > corticosteroids.> > > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Eckert+ T%22%5BAuthor% 5D> Eckert T, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Bartels+ C%22%5BAuthor% 5D> Bartels C, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Mawrin+ C%22%5BAuthor% 5D> Mawrin C, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Feistner +H%22%5BAuthor% 5D> Feistner H, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Welte+ T%22%5BAuthor% 5D> Welte T. > > > > Department of Pneumology, Medical School of Hannover, Carl-Neuberg-> Str. 1,> > 30625 Hannover, Germany.> > > > We report a case of a 62-y-old male developing an influenza > vaccination> > induced Guillain Barre syndrome (GBS) showing all clinical and> > neuropathological symptoms of GBS except the characteristic > elevation of> > protein levels in the cerebrospinal fluid. The patient improved > under> > treatment with 100 mg prednisolone. In these cases the > administration of> > corticosteroids might be considered as a treatment option as they > might> > represent a subgroup of GBS with a different immunological > response pattern.> > > > PMID: 16138440 [PubMed - indexed for MEDLINE]> > > > > > > > -----> > > > > > > > > > Guillain-Barre syndrome following influenza vaccination.> > > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Haber+ P%22%5BAuthor% 5D> Haber P, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22DeStefan o+F%22%5BAuthor% 5D> DeStefano F, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Angulo+ FJ%22%5BAuthor% 5D> Angulo FJ, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Iskander +J%22%5BAuthor% 5D> Iskander J, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Shadomy+ SV%22%5BAuthor% 5D> Shadomy SV, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Weintrau b+E%22%5BAuthor% 5D> Weintraub E, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Chen+ RT%22%5BAuthor% 5D> Chen RT. > > > > Immunization Safety Branch, Epidemiology and Surveillance > Division, National> > Immunization Program, Centers for Disease Control and Prevention, > Atlanta,> > Ga 30333, USA. PHaber@> > > > CONTEXT: An unexplained increase in the risk of Guillain-Barre > syndrome> > (GBS) occurred among recipients of the swine influenza vaccine in > 1976-1977.> > Guillain-Barre syndrome remains the most frequent neurological > condition> > reported after influenza vaccination to the Vaccine Adverse Events > Reporting> > System (VAERS) since its inception in 1990. OBJECTIVE: To evaluate > trends of> > reports to VAERS of GBS following influenza vaccination in adults. > DESIGN,> > SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous > reporting> > system for adverse events following vaccination. Reports of GBS in > persons> > 18 years or older following influenza vaccination were evaluated > for each> > influenza season from July 1, 1990, through June 30, 2003. The > number of> > people vaccinated was estimated from the National Health Interview > Survey> > and US census data. Beginning in 1994, active follow-up was > conducted to> > verify GBS diagnosis and obtain other clinical details. MAIN > OUTCOME> > MEASURE: Reporting rates of GBS following influenza vaccination > over time.> > RESULTS: From July 1990 through June 2003, VAERS received 501 > reports of GBS> > following influenza vaccination in adults. The median onset > interval (13> > days) was longer than that of non-GBS reports of adverse events > after> > influenza vaccine (1 day) (P<.001). The annual reporting rate > decreased> > 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to > 0.04 in> > 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of > reports.> > Preceding illness within 4 weeks of vaccination was identified in > 24% of> > reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting > rates of GBS> > after influenza vaccination decreased. The long onset interval and > low> > prevalence of other preexisting illnesses are consistent with a > possible> > causal association between GBS and influenza vaccine. These > findings require> > additional research, which can lead to a fuller understanding of > the causes> > of GBS and its possible relationship with influenza vaccine.> > > > PMID: 15562126 [PubMed - indexed for MEDLINE]> > > > > > > > ---> > > > > > > > > > Influenza vaccination and Guillain Barre syndrome small star, > filled.> > > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Geier+ MR%22%5BAuthor% 5D> Geier MR, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Geier+ DA%22%5BAuthor% 5D> Geier DA, > > > > *> > <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?> db=pubmed & cmd= Search & itool= pu> > bmed_AbstractPlus & term=%22Zahalsky +AC%22%5BAuthor% 5D> Zahalsky AC. > > > > The Genetic Centers of America, 14 Redgate Court, Silver Spring, > MD 20905,> > USA. mgeier@ <mgeier@>> > > > Acute and severe Guillain Barre Syndrome (GBS) cases reported > following> > influenza vaccine to the Vaccine Adverse Events Reporting System > (VAERS)> > database from 1991 through 1999 were examined. Endotoxin > concentrations were> > measured using the Limulus amebocyte lysate assay in influenza > vaccines.> > There were a total of 382 cases of GBS reported to the VAERS > database> > following influenza vaccination (male/female ratio, 1.2). The > median onset> > of GBS following influenza vaccine was 12 days (interquartile > range, 7 days> > to 21 days). There was an increased risk of acute GBS (relative > risk, 4.3;> > 95% confidence interval, 3.0 to 6.4) and severe GBS (relative > risk, 8.5; 95%> > confidence interval, 3.7 to 18.9) in comparison to an adult> > tetanus-diphtheria (Td) vaccine control group. There were maximums > in the> > incidence of GBS following influenza vaccine that occurred > approximately> > every third year (1993, 1996, and 1998) and statistically > significant> > variation in the incidence of GBS among different influenza > manufacturers.> > Influenza vaccines contained from a 125- to a 1250-fold increase in> > endotoxin concentrations in comparison to an adult Td vaccine > control and> > endotoxin concentrations varied up to 10-fold among different lots > and> > manufacturers of influenza vaccine. The biologic mechanism for GBS > following> > influenza vaccine may involve the synergistic effects of endotoxin > and> > vaccine-induced autoimmunity. There were minimal potential > reporting biases> > in the data reported to the VAERS database in this study. Patients > should> > make an informed consent decision on whether to take this optional > vaccine> > based upon its safety and efficacy and physicians should > vigilantly report> > GBS following influenza vaccination to the VAERS in the United > States so> > that continued evaluation of the safety of influenza vaccine may be> > undertaken.> > > > PMID: 12763480 [PubMed - indexed for MEDLINE]> > > > > > > > Qadoshyah > > <http://www.geocitie s.com/dsinfo05/ home.html>> >> > > > > ____________ _________ _________ _________ _________ __> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 20, 2006 Report Share Posted November 20, 2006 I see Carol gave you a bunch of info over the weekend (have yet to read through it all ). But, I thought I'd mention that the flu vaccine doesn't protect from every strand of the flu. I was just talking to my cousin (who's a paramedic) about this Saturday. There's SOOOOO many different strands of the flu and new ones (mutations) coming up all the time, the vaccine may only be effective (if it is effective at all ), with certain strands of the flu virus. But, a vaccine (this particular kind of vaccine) cannot cover ALL the many different strands. Just another thought. Some "other" advice for helping to keep the flu away - stay home, secluded from people, and up certain vitamins . Just my .02! Qadoshyah *Got Down Syndrome? www.gotdownsyndrome.net From: Down Syndrome Treatment [mailto:Down Syndrome Treatment ] On Behalf Of ztribemomSent: Friday, November 17, 2006 9:25 PMDown Syndrome Treatment Subject: Re: The Flu Vaccine Dear Qadoshyah,Thank you for this info. I have been struggling with this as Jack is scheduled for heart surgery very soon and I have not gotten the shot yet. (Or shots I should say.) All of his drs. recommend it. It is scary but, the package info. actually says in the contra-indications portion that it should not be administered to anyone with thimerosol sensitivity--I thought Fluzone was thimerosol free! Is it possible that the vaccine has been altered since the package insert was printed or that they change this each year? It also says not to administer to anyone under 6mos. of age. or who has a fever or any sign of illness. Aren't our heart babies chronically ill? This is supposed to be a dead vaccine--what is in there to cause these problems? You don't have to answer these ?? they are just my feeble brain ramblings!! Thankfully, God is still on His throne! Z.>> Some interesting links to info about the flu vaccine - > > http://www.nccn.net/~wwithin/flu.htm> > http://www.whale.to/vaccines/flu.html - this one has package inserts on it.> > > http://www.planetc1.com/cgi-bin/n/v.cgi?c=1> <http://www.planetc1.com/cgi-bin/n/v.cgi?c=1 & id=1163608370> & id=1163608370> Flu Vaccine increases risk for neurological disorder> planetc1.com-news@5:32 am PST <mailto:mail@...> email to the> editor> by Dorausch, DC> planetc1.com news staff > > It is important to be aware of the risks involved when considering taking> any drug or vaccine or putting a drug or vaccine into a young ones body. A> new study has revealed that the flu vaccine is associated with an increased> risk of developing a debilitating neurological disorder known as> Guillain-Barré syndrome. > > > The debilitating nerve destroying syndrome affects about one in 100,000> people each year. It results from the body's immune system attacking parts> of the nervous system, causing weakness or tingling that can eventually lead> to paralysis. Previous research had linked Guillain-Barré syndrome to the> flu vaccine, but researchers continue to look for more connections between> debilitating conditions and flu vaccines. > > > According to the National Institute of Neurological Disorders and Stroke,> Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in which the body's> immune system attacks part of the peripheral nervous system. The first> symptoms of this disorder include varying degrees of weakness or tingling> sensations in the legs. In many instances the weakness and abnormal> sensations spread to the arms and upper body. These symptoms can increase in> intensity until certain muscles cannot be used at all and, when severe, the> patient is almost totally paralyzed. > > > The research comes from the University of Toronto. Researchers studied> residents in Ontario, where a flu vaccine immunization program was started> in 2000. All Ontario residents 6 months or older received a FREE flu> vaccine. Researchers looked into cases of hospitalization for Guillain-Barré> syndrome from 1993 to 2004. They then researched who had received a flu> vaccine and compared the individuals risk for the syndrome within two to> seven weeks after vaccination up to twenty to forty-three weeks later.> Researchers also compared the number of Guillain-Barré cases before and> after the immunization program began in 2000. > > > Researchers discovered that Ontario residents were more likely to be> hospitalized for Guillain-Barré syndrome in the two to seven weeks after> being vaccinated than at forty-three weeks. It showed a small but increased> risk for the disease after vaccination. > > > There has been a lot of discussion whether the flu vaccine is even effective> in preventing the flu. Add to that, the risk of developing disabling nerve> disorders, mercury toxicity (from shots containing thimerosal), as well as> other side effects, and you may wonder we one would even subject themselves> to the shot. One thing is for sure, the more people that get the flu shot,> the more data researchers will have to determine what disorders and> conditions are caused by the shot.> > -- Doing a pubmed search for "Guillain-Barré syndrome flu> vaccine" yielded these results:> > > A case of influenza vaccination induced Guillain Barre syndrome with normal> cerebrospinal fluid protein and improvement on treatment with> corticosteroids.> > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Eckert+T%22%5BAuthor%5D> Eckert T, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Bartels+C%22%5BAuthor%5D> Bartels C, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Mawrin+C%22%5BAuthor%5D> Mawrin C, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Feistner+H%22%5BAuthor%5D> Feistner H, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Welte+T%22%5BAuthor%5D> Welte T. > > Department of Pneumology, Medical School of Hannover, Carl-Neuberg-Str. 1,> 30625 Hannover, Germany.> > We report a case of a 62-y-old male developing an influenza vaccination> induced Guillain Barre syndrome (GBS) showing all clinical and> neuropathological symptoms of GBS except the characteristic elevation of> protein levels in the cerebrospinal fluid. The patient improved under> treatment with 100 mg prednisolone. In these cases the administration of> corticosteroids might be considered as a treatment option as they might> represent a subgroup of GBS with a different immunological response pattern.> > PMID: 16138440 [PubMed - indexed for MEDLINE]> > > > -----> > > > > Guillain-Barre syndrome following influenza vaccination.> > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Haber+P%22%5BAuthor%5D> Haber P, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22DeStefano+F%22%5BAuthor%5D> DeStefano F, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Angulo+FJ%22%5BAuthor%5D> Angulo FJ, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Iskander+J%22%5BAuthor%5D> Iskander J, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Shadomy+SV%22%5BAuthor%5D> Shadomy SV, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Weintraub+E%22%5BAuthor%5D> Weintraub E, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Chen+RT%22%5BAuthor%5D> Chen RT. > > Immunization Safety Branch, Epidemiology and Surveillance Division, National> Immunization Program, Centers for Disease Control and Prevention, Atlanta,> Ga 30333, USA. PHaber@...> > CONTEXT: An unexplained increase in the risk of Guillain-Barre syndrome> (GBS) occurred among recipients of the swine influenza vaccine in 1976-1977.> Guillain-Barre syndrome remains the most frequent neurological condition> reported after influenza vaccination to the Vaccine Adverse Events Reporting> System (VAERS) since its inception in 1990. OBJECTIVE: To evaluate trends of> reports to VAERS of GBS following influenza vaccination in adults. DESIGN,> SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous reporting> system for adverse events following vaccination. Reports of GBS in persons> 18 years or older following influenza vaccination were evaluated for each> influenza season from July 1, 1990, through June 30, 2003. The number of> people vaccinated was estimated from the National Health Interview Survey> and US census data. Beginning in 1994, active follow-up was conducted to> verify GBS diagnosis and obtain other clinical details. MAIN OUTCOME> MEASURE: Reporting rates of GBS following influenza vaccination over time.> RESULTS: From July 1990 through June 2003, VAERS received 501 reports of GBS> following influenza vaccination in adults. The median onset interval (13> days) was longer than that of non-GBS reports of adverse events after> influenza vaccine (1 day) (P<.001). The annual reporting rate decreased> 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to 0.04 in> 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of reports.> Preceding illness within 4 weeks of vaccination was identified in 24% of> reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting rates of GBS> after influenza vaccination decreased. The long onset interval and low> prevalence of other preexisting illnesses are consistent with a possible> causal association between GBS and influenza vaccine. These findings require> additional research, which can lead to a fuller understanding of the causes> of GBS and its possible relationship with influenza vaccine.> > PMID: 15562126 [PubMed - indexed for MEDLINE]> > > > ---> > > > > Influenza vaccination and Guillain Barre syndrome small star, filled.> > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Geier+MR%22%5BAuthor%5D> Geier MR, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Geier+DA%22%5BAuthor%5D> Geier DA, > > *> <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itool=pu> bmed_AbstractPlus & term=%22Zahalsky+AC%22%5BAuthor%5D> Zahalsky AC. > > The Genetic Centers of America, 14 Redgate Court, Silver Spring, MD 20905,> USA. mgeier@... <mgeier@...>> > Acute and severe Guillain Barre Syndrome (GBS) cases reported following> influenza vaccine to the Vaccine Adverse Events Reporting System (VAERS)> database from 1991 through 1999 were examined. Endotoxin concentrations were> measured using the Limulus amebocyte lysate assay in influenza vaccines.> There were a total of 382 cases of GBS reported to the VAERS database> following influenza vaccination (male/female ratio, 1.2). The median onset> of GBS following influenza vaccine was 12 days (interquartile range, 7 days> to 21 days). There was an increased risk of acute GBS (relative risk, 4.3;> 95% confidence interval, 3.0 to 6.4) and severe GBS (relative risk, 8.5; 95%> confidence interval, 3.7 to 18.9) in comparison to an adult> tetanus-diphtheria (Td) vaccine control group. There were maximums in the> incidence of GBS following influenza vaccine that occurred approximately> every third year (1993, 1996, and 1998) and statistically significant> variation in the incidence of GBS among different influenza manufacturers.> Influenza vaccines contained from a 125- to a 1250-fold increase in> endotoxin concentrations in comparison to an adult Td vaccine control and> endotoxin concentrations varied up to 10-fold among different lots and> manufacturers of influenza vaccine. The biologic mechanism for GBS following> influenza vaccine may involve the synergistic effects of endotoxin and> vaccine-induced autoimmunity. There were minimal potential reporting biases> in the data reported to the VAERS database in this study. Patients should> make an informed consent decision on whether to take this optional vaccine> based upon its safety and efficacy and physicians should vigilantly report> GBS following influenza vaccination to the VAERS in the United States so> that continued evaluation of the safety of influenza vaccine may be> undertaken.> > PMID: 12763480 [PubMed - indexed for MEDLINE]> > > > Qadoshyah > <http://www.geocities.com/dsinfo05/home.html>> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2006 Report Share Posted November 21, 2006 It's very true that there a many flu virus' ( virii??) out there. They make an educated case which one will spread over here and sometimes they are wrong. They were really wrong a couple of years back, or was that just last year? All the virus that spread here, start in Asia somewhere. That's how they even know which ones to start with. It's pretty interesting. Amazing they ever get it right, but they do! I agree best method to avoid any of the viral infections out and about is to stay away from people! We did that for a year with Chrisitne and everyone only got sick once. It can be done, but you won't get much else done. :-) I also think that missing out on being exposed to a lot of stuff that first year, made her next couple of years pretty miserable when she was exposed to normal stuff.. but oh well. Couldn't be helped at the time. Her son is going to have to go into the hospital during flu/viral season and at a time when his body is even less able to fight things off. If it were me, I would check to see if they got the virus right this year for starters.....if they didn't, wouldn't be worth the risk. Carol in IL Mom to seven including , 6 with TOF, AVcanal, GERD, LS, Asthma, subglottal stenosis, chronic constipation ( cured now ) and DS. My problem is not how I look. It's how you see me. [DownSyndromeInfoEx change] Re: The Flu Vaccine Dear Qadoshyah,Thank you for this info. I have been struggling with this as Jack is scheduled for heart surgery very soon and I have not gotten the shot yet. (Or shots I should say.) All of his drs. recommend it. It is scary but, the package info. actually says in the contra-indications portion that it should not be administered to anyone with thimerosol sensitivity- -I thought Fluzone was thimerosol free! Is it possible that the vaccine has been altered since the package insert was printed or that they change this each year? It also says not to administer to anyone under 6mos. of age. or who has a fever or any sign of illness. Aren't our heart babies chronically ill? This is supposed to be a dead vaccine--what is in there to cause these problems? You don't have to answer these ?? they are just my feeble brain ramblings!! Thankfully, God is still on His throne! Z.>> Some interesting links to info about the flu vaccine - > > http://www.nccn. net/~wwithin/ flu.htm> > http://www.whale. to/vaccines/ flu.html - this one has package inserts on it.> > > http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1> <http://www.planetc1 .com/cgi- bin/n/v.cgi? c=1 & id=116360837 0> & id=1163608370> Flu Vaccine increases risk for neurological disorder> planetc1.com- news@5:32 am PST <mailto:mail@ ...> email to the> editor> by Dorausch, DC> planetc1.com news staff > > It is important to be aware of the risks involved when considering taking> any drug or vaccine or putting a drug or vaccine into a young ones body. A> new study has revealed that the flu vaccine is associated with an increased> risk of developing a debilitating neurological disorder known as> Guillain-Barré syndrome. > > > The debilitating nerve destroying syndrome affects about one in 100,000> people each year. It results from the body's immune system attacking parts> of the nervous system, causing weakness or tingling that can eventually lead> to paralysis. Previous research had linked Guillain-Barré syndrome to the> flu vaccine, but researchers continue to look for more connections between> debilitating conditions and flu vaccines. > > > According to the National Institute of Neurological Disorders and Stroke,> Guillain-Barré (ghee-yan bah-ray) syndrome is a disorder in which the body's> immune system attacks part of the peripheral nervous system. The first> symptoms of this disorder include varying degrees of weakness or tingling> sensations in the legs. In many instances the weakness and abnormal> sensations spread to the arms and upper body. These symptoms can increase in> intensity until certain muscles cannot be used at all and, when severe, the> patient is almost totally paralyzed. > > > The research comes from the University of Toronto. Researchers studied> residents in Ontario, where a flu vaccine immunization program was started> in 2000. All Ontario residents 6 months or older received a FREE flu> vaccine. Researchers looked into cases of hospitalization for Guillain-Barré> syndrome from 1993 to 2004. They then researched who had received a flu> vaccine and compared the individuals risk for the syndrome within two to> seven weeks after vaccination up to twenty to forty-three weeks later.> Researchers also compared the number of Guillain-Barré cases before and> after the immunization program began in 2000. > > > Researchers discovered that Ontario residents were more likely to be> hospitalized for Guillain-Barré syndrome in the two to seven weeks after> being vaccinated than at forty-three weeks. It showed a small but increased> risk for the disease after vaccination. > > > There has been a lot of discussion whether the flu vaccine is even effective> in preventing the flu. Add to that, the risk of developing disabling nerve> disorders, mercury toxicity (from shots containing thimerosal), as well as> other side effects, and you may wonder we one would even subject themselves> to the shot. One thing is for sure, the more people that get the flu shot,> the more data researchers will have to determine what disorders and> conditions are caused by the shot.> > -- Doing a pubmed search for "Guillain-Barré syndrome flu> vaccine" yielded these results:> > > A case of influenza vaccination induced Guillain Barre syndrome with normal> cerebrospinal fluid protein and improvement on treatment with> corticosteroids.> > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Eckert+ T%22%5BAuthor% 5D> Eckert T, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Bartels+ C%22%5BAuthor% 5D> Bartels C, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Mawrin+ C%22%5BAuthor% 5D> Mawrin C, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Feistner +H%22%5BAuthor% 5D> Feistner H, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Welte+ T%22%5BAuthor% 5D> Welte T. > > Department of Pneumology, Medical School of Hannover, Carl-Neuberg-Str. 1,> 30625 Hannover, Germany.> > We report a case of a 62-y-old male developing an influenza vaccination> induced Guillain Barre syndrome (GBS) showing all clinical and> neuropathological symptoms of GBS except the characteristic elevation of> protein levels in the cerebrospinal fluid. The patient improved under> treatment with 100 mg prednisolone. In these cases the administration of> corticosteroids might be considered as a treatment option as they might> represent a subgroup of GBS with a different immunological response pattern.> > PMID: 16138440 [PubMed - indexed for MEDLINE]> > > > -----> > > > > Guillain-Barre syndrome following influenza vaccination.> > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Haber+ P%22%5BAuthor% 5D> Haber P, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22DeStefan o+F%22%5BAuthor% 5D> DeStefano F, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Angulo+ FJ%22%5BAuthor% 5D> Angulo FJ, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Iskander +J%22%5BAuthor% 5D> Iskander J, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Shadomy+ SV%22%5BAuthor% 5D> Shadomy SV, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Weintrau b+E%22%5BAuthor% 5D> Weintraub E, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Chen+ RT%22%5BAuthor% 5D> Chen RT. > > Immunization Safety Branch, Epidemiology and Surveillance Division, National> Immunization Program, Centers for Disease Control and Prevention, Atlanta,> Ga 30333, USA. PHaber@...> > CONTEXT: An unexplained increase in the risk of Guillain-Barre syndrome> (GBS) occurred among recipients of the swine influenza vaccine in 1976-1977.> Guillain-Barre syndrome remains the most frequent neurological condition> reported after influenza vaccination to the Vaccine Adverse Events Reporting> System (VAERS) since its inception in 1990. OBJECTIVE: To evaluate trends of> reports to VAERS of GBS following influenza vaccination in adults. DESIGN,> SETTING, AND PARTICIPANTS: VAERS is the US national spontaneous reporting> system for adverse events following vaccination. Reports of GBS in persons> 18 years or older following influenza vaccination were evaluated for each> influenza season from July 1, 1990, through June 30, 2003. The number of> people vaccinated was estimated from the National Health Interview Survey> and US census data. Beginning in 1994, active follow-up was conducted to> verify GBS diagnosis and obtain other clinical details. MAIN OUTCOME> MEASURE: Reporting rates of GBS following influenza vaccination over time.> RESULTS: From July 1990 through June 2003, VAERS received 501 reports of GBS> following influenza vaccination in adults. The median onset interval (13> days) was longer than that of non-GBS reports of adverse events after> influenza vaccine (1 day) (P<.001). The annual reporting rate decreased> 4-fold from a high of 0.17 per 100,000 vaccinees in 1993-1994 to 0.04 in> 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of reports.> Preceding illness within 4 weeks of vaccination was identified in 24% of> reported cases. CONCLUSIONS: From 1990 to 2003, VAERS reporting rates of GBS> after influenza vaccination decreased. The long onset interval and low> prevalence of other preexisting illnesses are consistent with a possible> causal association between GBS and influenza vaccine. These findings require> additional research, which can lead to a fuller understanding of the causes> of GBS and its possible relationship with influenza vaccine.> > PMID: 15562126 [PubMed - indexed for MEDLINE]> > > > ---> > > > > Influenza vaccination and Guillain Barre syndrome small star, filled.> > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Geier+ MR%22%5BAuthor% 5D> Geier MR, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Geier+ DA%22%5BAuthor% 5D> Geier DA, > > *> <http://www.ncbi. nlm.nih.gov/ entrez/query. fcgi?db=pubmed & cmd= Search & itool= pu> bmed_AbstractPlus & term=%22Zahalsky +AC%22%5BAuthor% 5D> Zahalsky AC. > > The Genetic Centers of America, 14 Redgate Court, Silver Spring, MD 20905,> USA. mgeier@... <mgeier@...>> > Acute and severe Guillain Barre Syndrome (GBS) cases reported following> influenza vaccine to the Vaccine Adverse Events Reporting System (VAERS)> database from 1991 through 1999 were examined. Endotoxin concentrations were> measured using the Limulus amebocyte lysate assay in influenza vaccines.> There were a total of 382 cases of GBS reported to the VAERS database> following influenza vaccination (male/female ratio, 1.2). The median onset> of GBS following influenza vaccine was 12 days (interquartile range, 7 days> to 21 days). There was an increased risk of acute GBS (relative risk, 4.3;> 95% confidence interval, 3.0 to 6.4) and severe GBS (relative risk, 8.5; 95%> confidence interval, 3.7 to 18.9) in comparison to an adult> tetanus-diphtheria (Td) vaccine control group. There were maximums in the> incidence of GBS following influenza vaccine that occurred approximately> every third year (1993, 1996, and 1998) and statistically significant> variation in the incidence of GBS among different influenza manufacturers.> Influenza vaccines contained from a 125- to a 1250-fold increase in> endotoxin concentrations in comparison to an adult Td vaccine control and> endotoxin concentrations varied up to 10-fold among different lots and> manufacturers of influenza vaccine. The biologic mechanism for GBS following> influenza vaccine may involve the synergistic effects of endotoxin and> vaccine-induced autoimmunity. There were minimal potential reporting biases> in the data reported to the VAERS database in this study. Patients should> make an informed consent decision on whether to take this optional vaccine> based upon its safety and efficacy and physicians should vigilantly report> GBS following influenza vaccination to the VAERS in the United States so> that continued evaluation of the safety of influenza vaccine may be> undertaken.> > PMID: 12763480 [PubMed - indexed for MEDLINE]> > > > Qadoshyah > <http://www.geocitie s.com/dsinfo05/ home.html>>__________________________________________________ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.